REMARKS

The specification has been amended to comply with the attached Notice to Comply with

Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid

Sequence Disclosures dated November 21, 2008. No new matter is added by entry of this

amendment.

It is believed that no fee is due with this communication, however, should any fees under

37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed document, the

Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski Deposit

Account No. 50-1212/DEBE:059US.

The Examiner is invited to contact the undersigned attorney with any questions,

comments or suggestions relating to the referenced patent application.

Respectfully submitted,

Steven L. Highlander

Reg. No. 37,642 Attorney for Applicants

Austin, Texas 78701

(512) 474-5201

Date: January 22, 2008

FULBRIGHT & JAWORSKI L.L.P.

600 Congress Avenue, Suite 2400

Notice to Comply

Patentin Software Program Support

PatentIn Software is Available At www.USPTO.gov
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Application No. 10/536,932 KUFER ET AL.

Beaminer Art Unit

Molly E. Baughman 1637

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	 A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	 The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	 Other: The corrected sequence of SEQ ID NO:35 in the reply filed on 8/27/2005 was not accompanied by a dated Sequence Listing containing the corrected sequence in paper and computer readable form.
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically recting its entry into the application.
	A statement that the content of the paper and computer readable copies are the same and, where applicable ude no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (571) 272-0871 For CRF Submission Helo. call (571) 272-2510

Technical Assistance.1-866-217-9197 or 703-305-3028 or 571-272-6845